(000766.SZ)本周上漲15.62%,在醫(yī)藥板塊漲幅居前,但該概念其他相關(guān)個股表現(xiàn)一般。 “出?!毙孪κ袌鋈杂写碳?。11月17日,億帆醫(yī)藥(002019.SZ)盤中直線拉升,當(dāng)日收盤漲
審評中,包括和黃醫(yī)藥(00013.HK)呋喹替尼、億帆醫(yī)藥(002019.SZ)艾貝格司亭α等。安信證券醫(yī)藥團隊判斷,根據(jù)FDA審評期限,和黃醫(yī)藥呋喹替尼三線結(jié)直腸癌、百濟神州替雷利珠單抗食管癌二線適
熱評:
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 101.1 million yuan
地平片、奧美拉唑碳酸氫鈉膠囊(聯(lián)合申報),億帆醫(yī)藥(002019.SZ)全資子公司產(chǎn)品鹽酸多巴胺注射液,康恩貝(600572.SH)全資子公司產(chǎn)品乙酰半胱氨酸顆粒,匯宇制藥(688553.SH)的氟維
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 84.7 million yuan
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 44 million yuan
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 127.2 million yuan
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 150.3 million yuan
圖片
視頻
審評中,包括和黃醫(yī)藥(00013.HK)呋喹替尼、億帆醫(yī)藥(002019.SZ)艾貝格司亭α等。安信證券醫(yī)藥團隊判斷,根據(jù)FDA審評期限,和黃醫(yī)藥呋喹替尼三線結(jié)直腸癌、百濟神州替雷利珠單抗食管癌二線適
熱評:
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 101.1 million yuan
熱評:
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 101.1 million yuan
熱評:
地平片、奧美拉唑碳酸氫鈉膠囊(聯(lián)合申報),億帆醫(yī)藥(002019.SZ)全資子公司產(chǎn)品鹽酸多巴胺注射液,康恩貝(600572.SH)全資子公司產(chǎn)品乙酰半胱氨酸顆粒,匯宇制藥(688553.SH)的氟維
熱評:
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 84.7 million yuan
熱評:
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 44 million yuan
熱評:
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 127.2 million yuan
熱評:
Yifan Pharmaceutical Co.,Ltd. (億帆醫(yī)藥股份有限公司) (002019.SZ) reported a net profit of 150.3 million yuan
熱評: